BioCryst Announces Partnerships for Peramivir for Influenza Outsid...(s and 12000 points of vaccination reachi...),Health

• Neopharm Group for Israel
  

The Neopharm Group is a leading provider of innovative integrated solutions across the health care spectrum. Throughout the years the Group has evolved into a diversified health care company. Building leadership and combining strengths in the areas of branded pharmaceuticals and biological products, vaccines (including H1N1 vaccine), hospital products, orphan drugs, medical devices and diagnostics has enabled the Neopharm Group to become the 2nd largest group in the Israeli healthcare market with annual sales of more than U.S.$300 million.

"We are pleased to have established these relationships with strong partners who have extensive experience, capabilities, and regulatory contacts within these important markets," said Jon P. Stonehouse, President and Chief Executive Officer of BioCryst Pharmaceuticals. "In today's pandemic environment, such partnerships are the most expedient and effective option for getting peramivir to patients in need. BioCryst will continue to evaluate and develop partnerships outside the U.S. We are currently exploring other opportunities to expand the geographic reach of peramivir."

Peramivir U.S. Program Status

• The pre-emergency use authorization (EUA) review of intravenous (i.v.) peramivir announced in May has continued to progress. U.S. Government agencies are considering the future option of providing peramivir through an EUA in the event of a severe influenza outbreak with significant hospitalizations.
  

• BioCryst has finalized its plans for peramivir Phase 3 studies intended to support U.S. regulatory approval for influenza. Expenses for initial steps of the Phase 3 studies are covered under our original U.S. Department of Health and H
  '/>"/>